The decline matched the struggles of the broader stock market, though bright spots could be found with GenMark, Quidel, and NanoString all having good months.
In a recent study, Mills and his colleagues determined the platform has suitable throughput, quantitative performance, and reproducibility for the clinic.
The company aims to shore up its core nCounter platform business with new consumables, as it continues to work on new technologies and explore clinical translation.
The company's total revenues were $35.2 million during the quarter compared to $25.2 million during the same period in 2016. Full-year results also beat analyst estimates.
With multiple independent biomarkers, and potential combinations that may require even more subtyping, diagnostics to guide immunotherapy appears to be getting more complicated.
An analysis of several multigene breast cancer recurrence signatures suggests that some tests may be better than others at assessing risk of late distant recurrence.
At AGBT, researchers described applications for rapid pathogen ID; evaluating DNA, RNA, and gene expression in one assay; and understanding tumor heterogeneity.
Although a draft guidance last month recommended against use of molecular tests to guide chemotherapy, the group's finalized decision is subject to price negotiation and other adjustments.
Expectations for the full year exceeded prior guidance and analyst expectations and the firm said it believes it has put itself on a path to improved growth in 2018.
